Abstracts tagged "COVID-19"

Abstract Number: 1869 • ACR Convergence 2024
Analysis of Short-Term Side Effects Following COVID-19 Vaccination in Pregnancies Complicated by Autoimmune Inflammatory Rheumatic Diseases
Shunya Kaneshita¹, Christina Chambers², Diana Johnson¹, Arthur Kavanaugh¹, Richard Garfein¹ and Gretchen Bandoli¹, ¹University of California San Diego, La Jolla, CA, ²University of California, San Diego, La Jolla, CA
Background/Purpose: Pregnant women are particularly at risk of severe Coronavirus disease 2019 (COVID-19) infection, which is why the Centers for Disease Control and Prevention (CDC)…
Abstract Number: 2615 • ACR Convergence 2024
Prevalence of and Factors Associated with Developing Long COVID Among Patients with Autoimmune Rheumatic Diseases: A Retrospective Cohort Analysis of National U.S. Data
Namrata Singh¹, Jerrod Anzalone², Lesley Jackson³, Sandra Safo⁴, Zachary Butzin-Dozier⁵, Kaleb Michaud⁶, Holland Stevenson⁶, Maria I. ("Maio") Danila⁷, Jasvinder Singh⁸ and Rena Patel⁹, ¹University of Washington, Bellevue, WA, ²University of Nebraska Medical Center, Omaha, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Minnesota, Minneapolis, MN, ⁵University of California Berkeley School of Public Health, Berkeley, CA, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, ⁸Baylor College of Medicine, Birmingham, AL, ⁹University of Alabama at Birmingham, Birmingham
Background/Purpose: Patients with Autoimmune Rheumatic Diseases (AIRDs) are at higher risk of severe COVID-19 outcomes, with greater risk among those with multiple comorbidities, using specific…
Abstract Number: 0131 • ACR Convergence 2024
Methotrexate and Tumor Necrosis Factor Inhibitors Independently Decrease Neutralizing Antibodies After SARS-CoV-2 Vaccination: Updated Results from the SUCCEED Study
Carol Hitchon¹, Dawn Bowdish², Gilles Boire³, Paul Fortin⁴, Louis Flamand⁵, Vinod Chandran⁶, Roya M Dayam⁷, Anne-Claude Gingras⁸, Catherine Card⁹, Ines Colmegna¹⁰, Maggie Larche², Gil Kaplan¹¹, Luck Lukusa¹², Jennifer Lee¹² and Sasha Bernatsky¹³, and SUCCEED investigative team, ¹University of Manitoba, Winnipeg, MB, Canada, ²McMaster University, Hamilton, ON, Canada, ³Retired, Sherbrooke, QC, Canada, ⁴Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁵Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, ⁶University of Toronto, Toronto, ON, Canada, ⁷Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health, Toronto, ON, Canada, ⁸Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada, ⁹National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada, ¹⁰The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹¹University of Calgary, Calgary, AB, Canada, ¹²The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹³Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Given ongoing SARS-CoV-2 circulation, COVID-19 vaccination response in immune-mediated inflammatory disease (IMID) remains a key issue, particularly regarding effects of common immunosuppressives like methotrexate…
Abstract Number: 0246 • ACR Convergence 2024
Selectively Targeting TRBV11-2+ T Cells in Multisystem Inflammatory Syndrome in Children (MIS-C) Using Bispecific T Cell-Engaging Antibodies
Elana Shaw, Stephanie Glavaris, Brian Mog, Alexander Pearlman, Sarah DiNapoli, Jin Liu, Kyle J. Kaeo, Kenneth W. Kinzler, Chetan Bettegowda, Shibin Zhou, Bert Vogelstein, Suman Paul and Maximilian F. Konig, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a rare but potentially deadly immune complication after infection with SARS-CoV-2. In patients with MIS-C, a striking…
Abstract Number: 1880 • ACR Convergence 2024
Statewide Burden of Osteoarthritis in India and Its Trend from 1990-2021: A Benchmarking Analysis
Rafael Sanchez-Dopazo,¹, malay rathod², Ashwinikumar Shandilya³, Janmay Vala⁴, Eva Kalra⁵, Tapan Giri⁶, Saif Syed⁷, Mohit Lakkimsetti⁸, Juhi Patel⁹, VISHRANT AMIN¹⁰ and Hardik Desai¹¹, ¹Larkin Community Hospital Palm Springs Campus, Hialeah, FL, ²Monmouth Medical Center, Rutgers University, Ewing, NJ, ³Rural Medical college. Pravara institute of medical sciences., Ahmednagar, India, ⁴Terna Medical College, Navi Mumbai, Maharashtra, India, ⁵Trident Medical Cente, Charleston, SC, ⁶BJ Medical College, Pune, Pune, Maharashtra, India, ⁷Royal college of Surgeons,Dublin,Ireland, Dublin, Dublin, Ireland, ⁸Mamata Medical College,Khammam, Khammam, Telangana, India, ⁹GMERS MEDICAL COLLEGE VALSAD, 382330, Gujarat, India, ¹⁰GMERS MEDICAL COLLEGE VALSAD, Ahmedabad, India, ¹¹Gujarat Adani Institute of Medical Sciences, Bhuj, India
Background/Purpose: Osteoarthritis (OA) imposes a significant health burden globally, with India experiencing substantial demographic and epidemiological changes over the past three decades. This study addresses…
Abstract Number: 2616 • ACR Convergence 2024
Associations of Circulating Inflammatory Cytokines with Long COVID Among Patients with Systemic Autoimmune Rheumatic Diseases
Jeffrey Sparks¹, Xiaosong Wang², Pui Lee³, Kailey Brodeur⁴, Miao Lin⁵, Naomi Patel⁵, Yumeko Kawano⁶, Abigail Schiff⁷, Andrew King⁵, Jennifer Hanberg⁶, Shruthi Srivatsan⁵, Emily Kowalski⁶, Colebrook Johnson⁵, Kathleen Vanni⁶, Zachary Williams⁵, Grace Qian², Caleb Bolden⁵, Kevin Mueller⁶, Katarina Bade⁶, Alene Saavedra⁶, Rathnam Venkat⁸ and Zachary Wallace⁹, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ²Brigham and Women’s Hospital, Boston, MA, ³Boston Children's Hospital, Newton, MA, ⁴Boston Children's Hospital, Cumberland, RI, ⁵Massachusetts General Hospital, Boston, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital, Cambridge, MA, ⁸Tufts University School of Medicine, Boston, MA, ⁹Massachusetts General Hospital, Newton, MA
Background/Purpose: While the incidence of severe acute COVID-19 has decreased, post-acute sequelae of COVID-19 characterized by prolonged symptoms, or ‘long COVID,’ is common and associated…
Abstract Number: 0132 • ACR Convergence 2024
Patients with Systemic Autoimmune Rheumatic Diseases Remain at Risk for Hospitalization for COVID-19 Infection in the Omicron Era (2022-2024): A Retrospective Cohort Study
Naomi Patel¹, Andrew King¹, Shruthi Srivatsan¹, Xiaosong Wang², Emily Kowalski³, Kathleen Vanni³, Grace Qian², Jennifer Hanberg³, Katarina Bade³, Alene Saavedra³, Kevin Mueller³, Zachary Williams¹, Colebrook Johnson¹, Madison Negron¹, Jeffrey Sparks⁴ and Zachary Wallace⁵, ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women’s Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ⁵Massachusetts General Hospital, Newton, MA
Background/Purpose: The risk of severe acute COVID-19 infection has substantially decreased since the start of the pandemic. However, the risk of severe acute COVID-19 outcomes…
Abstract Number: 0366 • ACR Convergence 2024
Factors Associated with Participation in Rheumatology Clinical Trials: A UK-based Study
Koushan Kouranloo¹ and Chris Wincup², ¹Internal Medicine Resident., London, United Kingdom, ²King's College Hospital, London, United Kingdom
Background/Purpose: Clinicians are encouraged to consider patient preferences for offering face-to-face vs virtual consultations. This adaptability is particularly important to rheumatologists caring for patients with…
Abstract Number: 1888 • ACR Convergence 2024
Anti-Spike Antibodies Protect Against COVID-19 Infection in Immune-Mediated Inflammatory Diseases: Findings from the SUCCEED Study
Jeremiah Tan¹, J. Antonio Avina-Zubieta², Paul Fortin³, Anne-Claude Gingras⁴, Maggie Larche⁵, Dawn Bowdish⁵, Claudie Berger⁶, Ines Colmegna⁷, Carol Hitchon⁸, Diane Lacaille², Dawn Richards⁹, Nadine Lalonde¹⁰, Ayesha Kirmani¹, Jennifer Lee¹¹ and Sasha Bernatsky⁶, ¹Arthritis Research Canada, Vancouver, BC, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ³Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁴Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁷The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹Canadian Arthritis Patients Alliance, Toronto, ON, Canada, ¹⁰COVID-19 Global Rheumatology Alliance, London, ON, Canada, ¹¹The Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: People with immune-mediated inflammatory diseases (IMIDs) may be more vulnerable to severe COVID-19 outcomes. COVID-19 vaccination is a key element in mitigating this risk.…
Abstract Number: 2666 • ACR Convergence 2024
The Risk for Development of Myositis Is Not Increased After COVID-19 Vaccination Among U.S. Veterans
Caleb Hernandez¹, Naomi Schlesinger², Jorge Rojas³, Jessica A Walsh⁴, Tawnie Braaten², Gary Kunkel⁵, Makoto Jones², Sauer brian⁶, Julio Facelli¹, grant Cannon⁷ and Dorota Lebiedz-Odrobina⁸, ¹University of Utah, Salt Lake City, ²University of Utah, Salt Lake City, UT, ³Seattle VA, Mexico, Mexico, ⁴Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁷University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁸University of Utah, Cottonwood Heights, UT
Background/Purpose: Several case reports and case series of idiopathic inflammatory myositis (IIM) following COVID-19 vaccination have been reported. This study evaluated the association of prior…
Abstract Number: 0138 • ACR Convergence 2024
SARS-CoV-2 Vaccine Acceptance, Hesitancy and Uptake in a Cohort of Patients with Inflammatory Rheumatic Diseases (IRD)
iulia roman¹, Xenofon Baraliakos², Uta Kiltz³, Juergen Braun⁴ and Ioana Andreica⁵, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, ⁴Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: Vaccine acceptance is important to achieve high vaccination coverage and possibly herd immunity. Related to the evolution of the SARS-CoV-2 pandemic with its socio-political…
Abstract Number: 0718 • ACR Convergence 2024
Incidence and Patient Profile Changes in ANCA-Associated Vasculitis Following the SARS-CoV-2 Pandemic
Laura Ramos Ortiz de Zarate¹, Aresio Plaza Lopez², Alejandro mARTINEZ rODADO³, Maria Machattou¹, Pablo Navarro Palomo⁴, maria alonso de francisco³, Carlota Navarro Joven³, Natalia de la Torre-Rubio⁴, Olga Rusinovich⁵, Carolina Merino⁶, Blanca García Magallón⁷, Jose Campos Esteban⁷, hildegarda Godoy Tundidor⁸, Mónica Fernández Castro⁹, JESUS SANZ SANZ⁴, Carmen Barbadillo Mateos⁷, Carlos Maria Isasi Zaragoza⁷, Andrea Liso Andrino⁷, Maria Concepcion Sanchez Fernandez³ and Jose Luis Andreu⁴, ¹Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Spain, ²Hospital Puerta de Hierro Majadahonda, Madrid, Spain, ³Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Madrid, Spain, ⁴Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Spain, ⁵Hospital Universitario Puerta de Hierro Majadahonda., Boadilla del Monte, Spain, ⁶Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda (Madrid), Spain, ⁷Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Majadahonda, Madrid, Spain, ⁸Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Madrid, Spain, ⁹Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Madrid, Spain
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is often linked to previous viral infections. Clinical evidence suggests SARS-CoV-2 virus may follow a similar pattern, with an…
Abstract Number: 1897 • ACR Convergence 2024
People Living with Autoimmune Disease Are at Higher Risk of Suffering from Post-Acute Sequelae of SARS-CoV-2 but Immunization Is Protective
Shahdi Malakooti¹, Marc Abboud², Jennifer Murphy³, Nora Singer⁴ and Grace McComsey⁵, ¹MetroHealth at Case Western Reserve University, Cleveland, ²Saint Joseph Medical School, Beirut, Lebanon, ³University Hospitals, Cleveland, OH, ⁴MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH, ⁵University Hospitals at Case Western Reserve University, Cleveland
Background/Purpose: Post-Acute Sequelae of SARS-CoV-2 (PASC) include new or worsening of existing symptoms 3 months or more after SARS-CoV-2 infection. We have shown that vaccination…
Abstract Number: 0155 • ACR Convergence 2024
Comparative Analysis and Outcomes of COVID 19: Unveiling Trends in Rheumatological vs. Non-Rheumatological Disease Patients
Fizza Zulfiqar¹, Morgan Steele², Sharanya Shre Ezhilarasan Santhi³, Bryanna Singh², Jaisal Brar³, Sumit Raut³, Prami Nakarmi³, Samhitha Bitla Reddy³, Ojo Ayomide³, Bashar Roumia³, Fariha Tareen³, Nathan Crook³, Vanessa Drust³, Ahmed Fawzy Mohamed³, Asad Mohammad Jani³, Jennifer Orejuela³, Siena Captain³, Nikhil Vojalla³, Muhammad Bilal⁴, Rida Fatima⁴, Sanjana Kesireddy³, Paige Misner³, Rishab Prabhu³, Camelia Arsene³, Jawad Bilal⁵ and Jacky Duong³, ¹Trinity Health Oakland/Wayne State University, Pontiac, MI, ²Trinity Health Oakland, Pontiac, MI, ³Trinity Health Oakland, Pontiac, ⁴Bassett Medical Center, Cooperstown, NY, ⁵Southeast Tucson, Clinician Rheumatologist, Tuscon
Background/Purpose: COVID-19 has brought challenges for people with rheumatic diseases as well as those faced by the general population, such as increased risk of SARS-CoV-2…
Abstract Number: 0795 • ACR Convergence 2024
Prevalence of Post-exertional Malaise (PEM) in Adults with Rheumatic Diseases and Relationship with COVID19 Infection
Kaleb Michaud¹, Shreena Kamlesh Gandhi², Sofia Pedro³, Cassandra Calabrese⁴, Patti Katz⁵ and Leonard Calabrese⁶, ¹University of Nebraska Medical Center, Omaha, NE, ²Kansas University School of Medicine - Wichita, Wichita, KS, ³Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁴Cleveland Clinic Foundation, Cleveland Heights, OH, ⁵UCSF, San Rafael, CA, ⁶Cleveland Clinic, Cleveland, OH
Background/Purpose: Chronic fatigue is the dominant symptom in patients with Long COVID and Myalgic encephalomyelitis/Chronic fatigue syndrome (ME/CFS) as well as an important and prevalent…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].